GlassScriptPhysician profile
Rachel M Bates
NPI 1134905573
$7,646.99
in general payments reported to CMS, 2019-2025
25 companies · $3,305 in 2025
The $3,305 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $449 · 2024: $3,894 · 2025: $3,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,358 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,358.05 |
| Education | $288.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,382.78 | 2023-2025 | |
| Galderma Laboratories, L.P. | $848.34 | 2023-2025 | Aklief, Nemluvio |
| Arcutis Biotherapeutics, INC. | $705.85 | 2023-2025 | Zoryve |
| Genzyme Corporation | $623.51 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $599.09 | 2024-2025 | Dupixent |
| Ucb, INC. | $558.82 | 2024-2025 | Bimzelx |
| Incyte Corporation | $522.22 | 2023-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $445.45 | 2024-2025 | |
| Lilly USA, LLC | $258.88 | 2024-2025 | Ebglyss, Taltz |
| Leo Pharma INC. | $237.88 | 2023-2025 | Adbry, Anzupgo |
| Organon LLC | $177.67 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $161.48 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $155.12 | 2024 | Sotyktu |
| Amgen INC. | $139.92 | 2024-2025 | Otezla |
| Janssen Biotech, INC. | $132.77 | 2024-2025 | Tremfya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.27 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.85 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.53 | 2024 | Cabtreo |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Almirall LLC | $87.16 | 2024-2025 | Seysara |
| Botanix Sb INC | $52.33 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $49.55 | 2024 | |
| Dermavant Sciences, INC. | $39.06 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $24.94 | 2024 | Ycanth |
| Lnhc, INC | $18.57 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.